| __timestamp | Axsome Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 1213000 |
| Thursday, January 1, 2015 | 2419289 | 3425000 |
| Friday, January 1, 2016 | 6343648 | 6311000 |
| Sunday, January 1, 2017 | 7206691 | 9518000 |
| Monday, January 1, 2018 | 9351522 | 28080000 |
| Tuesday, January 1, 2019 | 13598030 | 36550000 |
| Wednesday, January 1, 2020 | 28896749 | 46125000 |
| Friday, January 1, 2021 | 66646205 | 68486000 |
| Saturday, January 1, 2022 | 159253661 | 92032000 |
| Sunday, January 1, 2023 | 323123000 | 117532000 |
| Monday, January 1, 2024 | 411359000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Axsome Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc. have been on this journey since 2014. Over the years, Axsome has seen a staggering increase in SG&A expenses, peaking at 323 million in 2023, a 23,000% rise from 2014. Rhythm Pharmaceuticals, while also experiencing growth, has managed a more modest increase of 9,600% over the same period, reaching 118 million in 2023.
Axsome's aggressive expansion strategy is evident in its SG&A trajectory, reflecting its commitment to scaling operations. In contrast, Rhythm's more conservative approach suggests a focus on sustainable growth. As these companies continue to evolve, their financial strategies will play a pivotal role in their success. Investors and industry watchers should keep a close eye on how these strategies unfold in the coming years.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited or Rhythm Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared